The addition of ianalumab to eltrombopag significantly improved outcomes for patients with pretreated primary immune ...

ITP is an autoimmune condition where the body’s immune cells mistakenly attack platelets, the blood cells responsible for clotting.

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an autoimmune ...

Scientists have discovered how a mitochondrial mutation rewires immune function in a model of inherited primary mitochondrial ...

Primary immune responses rely upon the successful contact between dendritic cells (DCs) and resting T cells, but exactly which molecules are involved in this process remains unknown. In April 15 ...

Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,262% of patients treated with ...

Immune thrombocytopenia (ITP) is an autoimmune disease in which IgG antiplatelet antibodies accelerate platelet clearance and reduce platelet production. The prevalence of ITP is approximately 1 to 3 ...

Weekly Carboplatin and Paclitaxel Followed by Concomitant Paclitaxel, Fluorouracil, and Hydroxyurea Chemoradiotherapy: Curative and Organ-Preserving Therapy for Advanced Head and Neck Cancer Purpose: ...

Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows ...